What You Should Know:
– Affidea, a pan-European provider of community-based polyclinics, specialist services, and advanced diagnostics, has announced a strategic collaboration with b-rayZ, a leader in AI-powered breast imaging solutions.
– The strategic partnership aims to revolutionize breast cancer diagnostics by streamlining the patient pathway, enhancing precision, and improving therapeutic options for women across Europe.
Enhancing Clinical Precision and Patient Outcomes
Affidea has chosen b-rayZ as its preferred AI partner for breast imaging, a decisive step towards making precision medicine a reality. The b-rayZ solution is already successfully in use at Affidea’s Centre of Excellence in Breast Cancer, Brust Zentrum Zurich, as well as at Affidea Givision, Site Hôpital Daler in Switzerland. Its technology has also been implemented in Affidea Lithuania and Affidea Spain, with further expansions planned in other Affidea countries offering breast imaging services. These early installations demonstrate growing confidence in b-rayZ’s ability to standardize and elevate diagnostic quality across diverse clinical environments.
The collaboration addresses the current fragmentation in breast cancer diagnostics, where critical information often scattered across different modalities and specialists can slow down decision-making and delay life-saving treatments . b-rayZ’s AI-powered platform is designed to eliminate these gaps, ensuring a seamless diagnostic pathway.
“Breast imaging is a highly specialised field that requires precision, experience, and the ability to interpret complex data. AI-powered solutions, like those developed by b-rayZ, are revolutionising breast cancer diagnostics by augmenting radiologists’ expertise and ensuring greater consistency in detection. Through this partnership, we are integrating AI to enhance our sub-specialty breast imaging, improving diagnostic accuracy, and optimising personalised screening pathways. This marks a significant step forward in delivering earlier diagnoses, reducing variability in interpretations, and ultimately ensuring the best possible clinical outcomes for women across Europe,” said Dr. Alessandro Roncacci, SVP and chief medical officer at Affidea.
